年轻乳腺癌患者局部复发的分子风险因素病例对照研究
该研究基于「Young Boost Trial」中≤50岁乳腺癌患者,采用病例对照设计比较局部复发者与无复发对照的原发肿瘤临床病理、拷贝数及基因表达特征,并比较原发灶与复发灶。结果显示5年局部复发率1.07%(95%CI 0.72-1.59%),10年2.56%(1.81-3.62%),复发灶与原发灶基因组特征相似,基底亚型与局部复发强相关,但未能识别局部复发的基因组分类器。
要点
- 5年局部复发率1.07%,10年2.56%,均为基因组真性复发
- 基底亚型在单因素和多因素分析中均与局部复发强相关
- 未识别出可用于预测局部复发的基因组分类器
核心结论
- 所有研究的局部复发均为真基因组复发,但未能识别局部复发的基因组分类器。
研究设计与样本
- 基于「Young Boost Trial」随机对照试验的病例对照研究,该试验纳入2421例≤50岁患者,随机接受16 Gy或26 Gy Boost。
- 比较局部复发患者(病例)与每例匹配3例无复发对照的临床病理、拷贝数及基因表达特征。
主要发现
- 5年局部复发率为1.07%(95%CI 0.72-1.59%),10年局部复发率为2.56%(95%CI 1.81-3.62%)。
- 原发肿瘤与局部复发的组织病理学特征(n=15)、拷贝数(n=13)和基因表达谱(n=14)相似。
- 基底亚型在单因素和多因素分析中均与局部复发强相关。
- 对照组中CCND1增益更常见,病例组中FGFR1和IGF1R增益更常见,复发肿瘤中p53通路基因上调。
临床怎么用
- 基底亚型可作为年轻乳腺癌患者局部复发的风险参考因素。
局限性
- 未能识别局部复发的基因组分类器,基因组差异分析样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate risk factors for local recurrence (LR) after breast conserving therapy in young breast cancer patients randomized in the "Young Boost Trial". MATERIAL & METHODS: In the "Young Boost Trial" 2421 patients ≤50 years old were randomized between a 16 Gy and 26 Gy boost after breast conserving surgery and whole breast radiation (50 Gy). We performed a case-control study comparing patients who developed a LR (cases) and for each of them three control patients free of recurrence (controls). Clinicopathological factors, copy number- and gene expression profiles of primary tumors were compared between cases and controls, and between primary tumors and local recurrences. RESULTS: The cumulative 5-year LR rate was 1.07% (95% CI 0.72-1.59%) and 10-year LR rate 2.56% (1.81-3.62%). Analysis of a subset of primary tumors and local recurrences showed similar histopathological characteristics (n = 15), copy number (n = 13) and gene expression profiles (n = 14). Basal subtype was strongly associated with LR in univariable and multivariable analysis. Gains of CCND1 were identified more frequently among controls, while more frequent gains of FGFR1 and IGF1R were observed among cases. Upregulation of genes involved in the p53-pathway was observed in recurring tumors compared to non-recurring tumors. We could not identify a genomic classifier for LR. CONCLUSIONS: All investigated local recurrences were true genomic recurrences. Although differences in copy number variation and gene expression pathways were observed in recurring tumors compared to non-recurring tumors, no genomic classifier for LR could be identified.
引用
- Bosma SCJ, Hoogstraat M, van Werkhoven E, et al. A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients. Radiother Oncol. 2020. PMID: 33245949. doi:10.1016/j.radonc.2020.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。